Dinaciclib
CAS No. 779353-01-4
Dinaciclib ( SCH 727965;SCH727965;SCH-727965 )
Catalog No. M15942 CAS No. 779353-01-4
A potent and selective CDK inhibitor with IC50 of 1, 1, 3 and 4 nM against CDK2, CDK5, CDK1 and CDK9, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 42 | In Stock |
|
5MG | 68 | In Stock |
|
10MG | 109 | In Stock |
|
50MG | 348 | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDinaciclib
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent and selective CDK inhibitor with IC50 of 1, 1, 3 and 4 nM against CDK2, CDK5, CDK1 and CDK9, respectively.
-
DescriptionA potent and selective CDK inhibitor with IC50 of 1, 1, 3 and 4 nM against CDK2, CDK5, CDK1 and CDK9, respectively; completely suppresses Rb phosphorylation and inhibits bromodeoxyuridine incorporation in >100 tumor cell lines; exhibits superior activity with an improved therapeutic index compared with flavopiridol.Blood Cancer Phase 3 Clinical
-
SynonymsSCH 727965;SCH727965;SCH-727965
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK1;CDK2;CDK5;CDK9
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number779353-01-4
-
Formula Weight396.49
-
Molecular FormulaC21H28N6O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 56 mg/mL
-
SMILESOCC[C@H]1N(C2=NC3=C(CC)C=NN3C(NCC4=C[N+]([O-])=CC=C4)=C2)CCCC1
-
Chemical Name2-Piperidineethanol, 1-[3-ethyl-7-[[(1-oxido-3-pyridinyl)methyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]-, (2S)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Parry D, et al. Mol Cancer Ther. 2010 Aug;9(8):2344-53.
2. Paruch K, et al. ACS Med Chem Lett. 2010 May 17;1(5):204-8.
3. Feldmann G, et al. Cancer Biol Ther. 2011 Oct 1;12(7):598-609.
4. Johnson AJ, et al. Leukemia. 2012 Dec;26(12):2554-7.
2. Paruch K, et al. ACS Med Chem Lett. 2010 May 17;1(5):204-8.
3. Feldmann G, et al. Cancer Biol Ther. 2011 Oct 1;12(7):598-609.
4. Johnson AJ, et al. Leukemia. 2012 Dec;26(12):2554-7.
molnova catalog
related products
-
JH-VIII-49
JH-VIII-49 is a potent and selective inhibitor of CDK8 with IC50 of 16 nM, also inhibits CDK19 (IC50=8 nM).
-
CDK4-IN-1
CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM.
-
Bohemine
Bohemine is a cyclin-dependent kinase inhibitor.